教員・教室員について

  1. TOP
  2. 教員・教室員について
  3. 教員・教室員紹介
  4. 教員
  5. 第一内科
  6. 綾野 雅宏（あやの まさひろ）

助教

研究教育活動

名前 綾野 雅宏（あやの まさひろ）
卒業年 2005（平成17）年
学位取得年月 2015年10月 医学博士学位取得
専門領域 膠原病リウマチ学、臨床免疫学
資格 日本内科学会認定内科医、総合内科専門医、日本リウマチ学会専門医・指導医・評議員
所属学会 日本内科学会、日本リウマチ学会、日本臨床免疫学会、日本補体学会

略歴

2005年4月

 倉敷中央病院　教育研修部　初期研修医

2007年4月

 倉敷中央病院　内分泌代謝・リウマチ内科　後期研修医

2010年4月

 九州大学病院　免疫・膠原病・感染症内科　医員

2011年4月

 九州大学大学院　医学系学府医学専攻　博士課程

2015年4月

 九州大学病院　遺伝子・細胞療法部　医員

2016年4月

 九州大学医学研究院　応用幹細胞医科学部門　がん幹細胞医学分野　助教
2023年４月

九州大学病院 免疫・膠原病・感染症内科 助教
現在に至る

代表的業績

  1. Ayano M, et al. Increased CD226 Expression on CD8+ T Cells Is Associated with Upregulated Cytokine Production and Endothelial Cell Injury in Patients with Systemic Sclerosis. J Immunol 195(3):892-900,2015.
  2. Ayano M, et al. CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I/II clinical trial conducted in Japan. Arthritis Res Ther 2019;21:30.
  3. Ayano M, et al. Shoulder ultrasound and serum lactate dehydrogenase predict inadequate response to glucocorticoid treatment in patients with polymyalgia rheumatica. Rheumatol Int 2020;40(7):1101-1109.
  4. Nakano M, Ayano M, et al. Increased Proportion of CD226 + B Cells Is Associated With the Disease Activity and Prognosis of Systemic Lupus Erythematosus. Front Immunol. 2021;12:713225. 
  5. Nakano M, Ayano M, et al. Association of elevated serum soluble CD226 levels with the disease activity and flares of systemic lupus erythematosus. Sci Rep. 2021;11(1):16162.
  6. Kushimoto K, Ayano M, et al. HLA-B52 allele in giant cell arteritis may indicate diffuse large-vessel vasculitis formation: a retrospective study. Arthritis Res Ther. 2021;23(1):238.
  7. Ayano M, et al. Hydroxychloroquine versus tacrolimus for the treatment of persistently active systemic lupus erythematosus. Mod Rheumatol. 2022;32(2):345-350.
  8. Ayano M, et al. Comparative efficacy and safety of mizoribine and mycophenolate mofetil for treating systemic lupus erythematosus: a retrospective cohort study. Ther Adv Musculoskelet Dis. 2022;14:1759720X221096367.
  9. Ayano M, et al. Safety and Efficacy of Switching Immunosuppressive Drugs for Maintenance Treatment in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study. Mod Rheumatol. 2023;33(5):961-967.
  10. Ayano M, et al. Complement as a Biomarker for Systemic Lupus Erythematosus. Biomolecules. 2023;13(2):367.
  11. Ayano M, et al. Comparing the safety and efficacy of nintedanib starting dose in patients with connective tissue disease-associated interstitial lung diseases. Scand J Rheumatol. 2024;53(4):255-262.
  12. Ayano M, et al. No clear influence of treatment escalation on flare prevention in serologically active clinically quiescent patients with systemic lupus erythematosus: a retrospective cohort study. Rheumatol Int. 2024;44(11):2411-2419.
  13. Ayano M, et al. Treatment selection in the clinical practice of systemic lupus erythematosus: results from the Kyushu Collagen Disease Network for Systemic Lupus Erythematosus (KCDN-SLE) registry. Mod Rheumatol. 2024;35:102-109.
  14. Kimura K, Ayano M, et al. Comparative efficacy and safety of belimumab and hydroxychloroquine in the maintenance phase in patients with systemic lupus erythematosus: a retrospective cohort study. Front Lupus. 2024;2:1459949.
  15. Ayano M, et al. Comparative efficacy and safety of anifrolumab for belimumab-experienced and biologic-naïve patients with systemic lupus erythematosus: results from the Kyushu Collagen Disease Network for Systemic Lupus Erythematosus (KCDN-SLE) registry. Joint Bone Spine. 2025:105882. doi: 10.1016/j.jbspin.2025.105882. 
  16. Nakano M, Ayano M, et al. Elevated soluble CD226 in Takayasu arteritis is useful for differentiation from giant cell arteritis, disease activity assessment, and prognosis prediction. Medicine (Baltimore). 2025;104:e42844.
  17. Hiura R, Ayano M, et al. Efficacy and safety of rituximab versus intravenous cyclophosphamide for systemic sclerosis-associated interstitial lung disease: a retrospective cohort study. Arthritis Res Ther. 2025;27:193.
  18. Ayano M, et al. Effectiveness, Tolerability, and Safety of Mepolizumab Injection Spacing in Patients With Eosinophilic Granulomatosis With Polyangiitis: A Retrospective Cohort Study. J Clin Rheumatol. 2026 Jan 30. doi: 10.1097/RHU.0000000000002321. Epub ahead of print.

一覧